Segment Disclosures (Tables)

3 Months Ended

Sep. 30, 2023

Summary of segment data for sales, cost of sales and gross margin

Segment data for sales, cost of sales and gross margin for the three and nine months ended September 30, 2023 and 2022 are presented in the table below.



	Ammonia		Granular Urea(1)		UAN(1)		AN(1)		Other(1)		Consolidated
	(in millions)
Three months ended September 30, 2023
Net sales	$	235	$	360	$	435	$	114	$	129	$	1,273
Cost of sales	214		226		302		79		75		896
Gross margin	$	21	$	134	$	133	$	35	$	54	377
Total other operating costs and expenses											97
Equity in losses of operating affiliate(2)											(36)
Operating earnings											$	244
Three months ended September 30, 2022
Net sales	$	531	$	689	$	736	$	180	$	185	$	2,321
Cost of sales	353		394		414		136		108		1,405
Gross margin	$	178	$	295	$	322	$	44	$	77	916
Total other operating costs and expenses(3)											186
Equity in earnings of operating affiliate											20
Operating earnings											$	750

Nine months ended September 30, 2023
Net sales	$	1,184	$	1,431	$	1,650	$	377	$	418	$	5,060
Cost of sales	797		775		937		264		243		3,016
Gross margin	$	387	$	656	$	713	$	113	$	175	2,044
Total other operating costs and expenses											228
Equity in losses of operating affiliate(2)											(12)
Operating earnings											$	1,804
Nine months ended September 30, 2022
Net sales	$	2,286	$	2,287	$	2,727	$	656	$	622	$	8,578
Cost of sales	1,075		1,024		1,102		458		314		3,973
Gross margin	$	1,211	$	1,263	$	1,625	$	198	$	308	4,605
Total other operating costs and expenses(3)											493

Equity in earnings of operating affiliate											74
Operating earnings											$	4,186

_______________________________________________________________________________

(1)The cost of the products that are upgraded into other products is transferred at cost into the upgraded product results.

(2)Equity in losses of operating affiliate for the three and nine months ended September 30, 2023 include an impairment of our equity method investment in PLNL of $43 million. See Note 7—Equity Method Investment for additional information.

(3)Total other operating costs and expenses for the three and nine months ended September 30, 2022 include $95 million and $257 million, respectively, of asset impairment and restructuring charges related to our U.K. operations. See Note 5—United Kingdom Operations Restructuring for additional information.